LONDON (AFX) - Biomedical venture capital specialist Abingworth said it has closed its 300 mln stg life sciences fund, Abingworth Bioventures V LP, which will invest in biotechnology and medical companies in Europe and the US.
LONDON (AFX) - Biomedical venture capital specialist Abingworth said it has closed its 300 mln stg life sciences fund, Abingworth Bioventures V LP, which will invest in biotechnology and medical companies in Europe and the US.